Melike Yılmaz, Cüneyt Toprak, Gökay Gün, Mahmut Özbek
Ivermectin has antiviral activity which may play an important role in several essential biological processes. Hence, it could be a potential candidate in the treatment of different kinds of viruses including COVID-19. Objective of this study was to formulate Ivermectin 3 mg Tablet to improve particle size distribution homogeniously. Three lab-scale trials and pilot study were performed with different batch size equipment to provide ideal filling ratio providing homogeniously blending. The manufacturing process was optimised in Trial-3 and then proses validation working was confirmed. Acceptable value of content uniformity of Trial-3 and pilot study was calculated as 3.93% and 3.71%, respectively. This study was indicated the importance of selecting suitable equipment to reach ideal blending in low dose tablet formulation by direct compression method.